High Density of FOXP3 Predicts Better Prognosis in Germinal and Non-germinal Centre Diffuse Large B-cell Lymphoma

Overview

Journal Int J Exp Pathol

Publisher Wiley

Specialty Pathology

Date 2023 Mar 28

PMID 36974470

Authors

Asmaa M Ahmed

Sally S Abdel-Hakeem

Maged A F Amine

Etemad H Yassin

Fatma A M Badary

Affiliations

Soon will be listed here.

Abstract

This study highlights the prognostic impact of FOXP3 and CD68 expression in DLBCL, NOS and in its GCB and non-GCB subtypes. This may help the development of individualized therapy, prognostic prediction and therapy stratification.

Citing Articles

High density of FOXP3 predicts better prognosis in germinal and non-germinal centre diffuse large B-cell lymphoma.

Ahmed A, Abdel-Hakeem S, Amine M, Yassin E, Badary F Int J Exp Pathol. 2023; 104(3):128-139.

PMID: 36974470 PMC: 10182367. DOI: 10.1111/iep.12477.

References

Kwak J . Treatment of diffuse large B cell lymphoma. Korean J Intern Med. 2012; 27(4):369-77. PMC: 3529233. DOI: 10.3904/kjim.2012.27.4.369. View

Coutinho R, Clear A, Mazzola E, Owen A, Greaves P, Wilson A . Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP. Haematologica. 2014; 100(3):363-9. PMC: 4349275. DOI: 10.3324/haematol.2014.110189. View

Tamma R, Ranieri G, Ingravallo G, Annese T, Oranger A, Gaudio F . Inflammatory Cells in Diffuse Large B Cell Lymphoma. J Clin Med. 2020; 9(8). PMC: 7463675. DOI: 10.3390/jcm9082418. View

Shi H, Chi H . Metabolic Control of Treg Cell Stability, Plasticity, and Tissue-Specific Heterogeneity. Front Immunol. 2020; 10:2716. PMC: 6917616. DOI: 10.3389/fimmu.2019.02716. View

Forssell J, Oberg A, Henriksson M, Stenling R, Jung A, Palmqvist R . High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res. 2007; 13(5):1472-9. DOI: 10.1158/1078-0432.CCR-06-2073. View

Riihijarvi S, Fiskvik I, Taskinen M, Vajavaara H, Tikkala M, Yri O . Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial. Haematologica. 2014; 100(2):238-45. PMC: 4803141. DOI: 10.3324/haematol.2014.113472. View

Shen L, Li H, Shi Y, Wang D, Gong J, Xun J . M2 tumour-associated macrophages contribute to tumour progression via legumain remodelling the extracellular matrix in diffuse large B cell lymphoma. Sci Rep. 2016; 6:30347. PMC: 4964568. DOI: 10.1038/srep30347. View

Swerdlow S, Campo E, Pileri S, Lee Harris N, Stein H, Siebert R . The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20):2375-90. PMC: 4874220. DOI: 10.1182/blood-2016-01-643569. View

Abdulla M, Hollander P, Pandzic T, Mansouri L, Ednersson S, Andersson P . Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma. Am J Hematol. 2019; 95(1):57-67. PMC: 6916573. DOI: 10.1002/ajh.25666. View

10.

Gomez-Gelvez J, Salama M, Perkins S, Leavitt M, Inamdar K . Prognostic Impact of Tumor Microenvironment in Diffuse Large B-Cell Lymphoma Uniformly Treated With R-CHOP Chemotherapy. Am J Clin Pathol. 2016; 145(4):514-23. DOI: 10.1093/ajcp/aqw034. View

11.

Shi X, Liu X, Li X, Li Y, Lu D, Sun X . Risk Stratification for Diffuse Large B-Cell Lymphoma by Integrating Interim Evaluation and International Prognostic Index: A Multicenter Retrospective Study. Front Oncol. 2022; 11:754964. PMC: 8716489. DOI: 10.3389/fonc.2021.754964. View

12.

Peng F, Qin Y, Mu S, Li J, Ai L, Hu Y . Prognostic role of regulatory T cells in lymphoma: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2020; 146(12):3123-3135. DOI: 10.1007/s00432-020-03398-1. View

13.

Ichiki A, Carreras J, Miyaoka M, Kikuti Y, Jibiki T, Tazume K . Clinicopathological Analysis of 320 Cases of Diffuse Large B-cell Lymphoma Using the Hans Classifier. J Clin Exp Hematop. 2017; 57(2):54-63. PMC: 6158052. DOI: 10.3960/jslrt.17029. View

14.

Wang J, Ke X . The four types of Tregs in malignant lymphomas. J Hematol Oncol. 2011; 4:50. PMC: 3253040. DOI: 10.1186/1756-8722-4-50. View

15.

Stigliani S, Croce M, Morandi F, Scaruffi P, Rigo V, Carlini B . Expression of FOXP3, CD14, and ARG1 in Neuroblastoma Tumor Tissue from High-Risk Patients Predicts Event-Free and Overall Survival. Biomed Res Int. 2015; 2015:347867. PMC: 4486282. DOI: 10.1155/2015/347867. View

16.

Pan Y, Yu Y, Wang X, Zhang T . Tumor-Associated Macrophages in Tumor Immunity. Front Immunol. 2020; 11:583084. PMC: 7751482. DOI: 10.3389/fimmu.2020.583084. View

17.

Dehghani M, Kalani M, Golmoghaddam H, Ramzi M, Arandi N . Aberrant peripheral blood CD4 CD25 FOXP3 regulatory T cells/T helper-17 number is associated with the outcome of patients with lymphoma. Cancer Immunol Immunother. 2020; 69(9):1917-1928. PMC: 11027683. DOI: 10.1007/s00262-020-02591-y. View

18.

Matsuki E, Bohn O, El Jamal S, Pichardo J, Zelenetz A, Younes A . Lymphocyte-to-Monocyte Ratio May Serve as a Better Prognostic Indicator Than Tumor-associated Macrophages in DLBCL Treated With Rituximab. Appl Immunohistochem Mol Morphol. 2018; 27(8):572-580. PMC: 6374215. DOI: 10.1097/PAI.0000000000000645. View

19.

Salmi S, Lin A, Hirschovits-Gerz B, Valkonen M, Aaltonen N, Sironen R . The role of FoxP3+ regulatory T cells and IDO+ immune and tumor cells in malignant melanoma - an immunohistochemical study. BMC Cancer. 2021; 21(1):641. PMC: 8164759. DOI: 10.1186/s12885-021-08385-4. View

20.

Adalid-Peralta L, Fragoso G, Fleury A, Sciutto E . Mechanisms underlying the induction of regulatory T cells and its relevance in the adaptive immune response in parasitic infections. Int J Biol Sci. 2011; 7(9):1412-26. PMC: 3221948. DOI: 10.7150/ijbs.7.1412. View